Audit: QRS - Modified Citrus Pectin for Health & Longevity

Audit conducted on 26/08/2026 02:15 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values (4.8 g three times daily, 14.4 g total, 30 min before / 2 h after food, 15 g bolus), time-to-effect values, benefit/risk headings, contraindications, interactions, biomarker targets and cadence trace to ER lines 344–356, 399, 141–205, 229–273, 295–320, 429–450.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious framings preserved: “No trial has compared morning with evening dosing” (ER line 352), “The only dose with any controlled human exposure” (ER line 344), “The controlled cardiac trial found nothing at six months” (ER line 399), “No established target” for PSA (ER line 440).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy/breastfeeding and children below 5 years remain in the Contraindications gate, not the Caution gate; the conflicted cardiac benefit is not upgraded; “Gastrointestinal intolerance” remains High.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and Key Interactions both derive from ER Key Interactions & Contraindications (lines 293–320); Benefits from Expected Benefits; Risks from Potential Risks & Side Effects. No Benefit- or Risk-Modifying Factor is surfaced anywhere.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers or expert names appear. The only brand name, “PectaSol-C”, is used for the standard dose exactly as in ER line 344.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The deflationary, evidence-weighted framing of the ER Conclusion (lines 472–478) is carried through verbatim in tone.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Objective and data-driven throughout; the sheet gives the reader the concrete levers (dose, timing, biomarkers, decision points) to act on.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Values are stated descriptively (“Every human study split the daily amount into three”), not as instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No directive verbs; the footer disclaimer routes decisions to a qualified clinician.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrences of “recommend”, “advise”, “should” or “you”.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the sheet.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Retained technical terms are ER-sourced and necessary (biomarker names); “Dysphagia (difficulty swallowing)” is expanded exactly as in ER line 317.
2.8	Information is presented in a concise and very compact manner	🟢	ER magnitudes, p-values, citations and the ER table’s Context/Notes column are all stripped; items are reduced to key facts.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The sheet assumes a reader willing to run a 9-marker baseline panel and a 90-day reassessment cycle.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Thrice-daily dosing away from food and a repeated laboratory panel are presented without hedging about inconvenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No general-population simplification; full biomarker and interaction detail is retained.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance states the evidence has not earned confidence in either direction while the sheet still supplies the studied protocol and objective stopping criteria.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register is used outside At-A-Glance (“Pruritus and skin reactions”, “Gastrointestinal intolerance”, “Estimated glomerular filtration rate”); the plainer wording inside At-A-Glance is required by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present verbatim at lines 446, 492, 536, 606, 629, 779, 561, 574, 609/542/550/614/620, 633–635.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	The full variable set is present: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1–3 (label/value/sub), time_1–3 (label/value/sub), benefits_high/medium/low/speculative, stop_items, caution_items, risks_high/medium/low/speculative, marker_1–9 (name/target/why), monitoring_cadence, qualitative_item_1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable template spans website="evidence_review" (line 423), website="audit" (line 426) and website="full_review" (line 440) are untouched, as are the CSS block and footer disclaimer.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the High/Medium benefit and Medium risk tiers carry explanatory ER text rather than being empty, and are handled under items 12.5 / 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard dose”, “Timing within the day” and “Split rather than single dosing” match the ER bold labels at lines 344, 352 and 356 exactly.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit/risk item labels reproduce the ER #### headings; all nine marker names reproduce the ER table’s Biomarker column (lines 433–441).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present; the ER’s “⚠️ Conflicted” markers on gastrointestinal intolerance and the cardiac benefit are dropped, with tiering carried by CSS classes and <strong> labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to its per-section budget: magnitude paragraphs, p-values, PMIDs and the ER table’s Context/Notes column are removed, and the remaining item counts are those mandated by items 8.2, 9.2, 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed into the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: modified_citrus_pectin_2026-0826-0008_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0826-0200, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename modified_citrus_pectin_2026-0826-0008_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Confirmed across all eleven keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Modified Citrus Pectin for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic (ER line 8) with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Modified Citrus Pectin for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/26/2026”, the correct reformatting of 2026-0826-0200.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template subline; the ER’s “Also known as” line (ER line 30) is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Lines 434–438 compress all four Conclusion paragraphs (ER lines 472–478) into the decision-relevant bottom line.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Short-chain fibre and the two promoted uses → ER line 472; uncontrolled manufacturer-linked studies vs. two negative independent trials → ER line 474; low harm, bowel symptoms, itching → ER line 476; “not yet earned confidence in either direction” → ER line 478.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “galectin-3” is rendered as “a protein”, chelation as “shedding toxic metals”, uncontrolled design as “studies without a comparison group”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results; the trials are described only as having “found nothing”.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items map to the ER’s “Populations who should avoid Modified Citrus Pectin” list (ER lines 313–320).
8.2	[stop_items] represent the Contraindications from the ER	🟢	One-to-one coverage of all six ER populations: citrus allergy, bowel obstruction, dysphagia, advanced kidney impairment, pregnancy/breastfeeding, children below 5 years.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 564–569, each item in its own <li>.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationales “since mobilised metal and the absorbed fraction both clear renally” and “for whom no safety data of any kind exist” are stripped; the leading “Anyone with” is dropped throughout.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(estimated filtration rate below 30 mL/min/1.73 m²)”, “(difficulty swallowing)” and “(outside supervised treatment of documented lead poisoning)” are all retained; “severe” is kept on gastroparesis.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map to the ER’s interaction bullets at lines 295–311.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine ER interaction bullets are carried, including the ER’s explicit “Valproic acid: no interaction” finding; none duplicates a Contraindication item.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 577–596, each item in its own <li>.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All Caution/Monitor tags, mechanisms and mitigations from the ER bullets are stripped, as is the PMID 25544113 and PMID 9357093 citation detail.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER drug list is retained: levothyroxine/digoxin/warfarin/lithium; ferrous sulfate/calcium carbonate/zinc gluconate; calcium carbonate/omeprazole/esomeprazole; vitamin D/E/beta-carotene/lutein; sodium alginate/chlorella/activated charcoal/bentonite clay; succimer/calcium disodium edetate; nintedanib/pembrolizumab.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names multiple such interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action cells derive from ER Therapeutic Protocol bullets at lines 344, 352 and 356.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing relative to food, and split-versus-bolus dosing are the three implementation decisions the ER protocol turns on; the remaining bullets (half-life, genetic, sex, age, baseline biomarkers) are informational or covered by the Monitoring card.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains twelve bullets, well above three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Nine of nine sub-variables populated (lines 450–487), each traceable to ER protocol text; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Metal excretion, prostate marker and cardiac endpoints are exactly the three horizons named in the ER’s “Time to effect” bullet (ER line 399).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order matches the ER’s Low-tier benefit ordering and magnitudes: metal excretion (ER line 155, up to ~560%), PSA doubling time (ER line 161, 75% responders), cardiac endpoints (ER line 179, between-group non-significant).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names three distinct time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Nine of nine sub-variables populated (lines 498–528): “24 hours to 6 days”, “6 months”, “Nothing at 6 months”, each with an ER-derived sub-line.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information (line 399), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eleven listed items map to the #### headings in ER lines 151–205.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 538, 539, 540 and 548.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is reduced to its ER heading; every Magnitude line, p-value and manufacturer-linkage caveat is stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in either benefits list.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states no benefit reaches High or Medium (lines 143, 147); both spans are empty with style="display: none" at lines 538–539.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven listed items map to the #### headings in ER lines 231–273.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 608, 611, 612 and 618.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Adherence percentages, diarrhoea/flatulence rates and the beta-carotene crossover detail are all stripped; the ER’s “⚠️ Conflicted” tag on gastrointestinal intolerance is dropped per item 4.4.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks list.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states no risk reaches Medium (line 239); the span is empty with style="display: none" at line 611.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The nine table rows reproduce the ER Monitoring Protocol & Defining Success table (ER lines 431–441).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine present: galectin-3, estimated glomerular filtration rate, whole blood lead, urine toxic-metals panel, ferritin, serum zinc, high-sensitivity C-reactive protein, prostate-specific antigen, full blood count — with targets matching the ER’s Optimal Functional Range column exactly.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 770–772 reproduce the ER cadence sentence (ER line 429): 4 weeks, 12 weeks, then every 6 months, with metal panels each 90-day round.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items map to the ER’s qualitative marker list at lines 445–450.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Stool form and frequency, bloating and abdominal cramping, energy through the day, cognitive clarity and word-finding, sleep continuity, and skin itch — all six present at lines 782–801, with the ER’s trailing rationales trimmed.

Issues 26/08/2026 02:15

Pass rate 100.00%. No issues found.

Issues 26/08/2026 02:08

1. 1.3 / 2.5 — Prohibition not in the ER: [action_3_value] at line 481 reads “Three doses, never one bolus”; the ER (line 356) only reports that every human study split the dose and that a single bolus is untested, so “never” both strengthens the ER claim and turns a finding into an instruction.
2. 7.4 — Research-methods term in At-A-Glance: “uncontrolled studies” at line 435 is a technical classification a non-specialist would read as “poorly run”; the ER’s own Conclusion uses the plain “had no comparison group” (ER line 474).

Fixes 26/08/2026 02:08

1. 1.3 / 2.5 — Prohibition removed from protocol cell: [action_3_value] changed from “Three doses, never one bolus” to “Three doses rather than one bolus”, so the cell reports what the studies did instead of issuing a prohibition the ER never makes.
2. 7.4 — Plain wording for study design: [at_a_glance] now reads “studies without a comparison group” instead of “uncontrolled studies”, matching the ER Conclusion’s own plain phrasing; “the spread of cancer” was tightened to “cancer spread” to hold the section at 59 words.